X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2560) 2560
Publication (250) 250
Book Review (32) 32
Magazine Article (8) 8
Book Chapter (6) 6
Conference Proceeding (6) 6
Book / eBook (2) 2
Reference (2) 2
Dissertation (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (1615) 1615
animals (1458) 1458
humans (1329) 1329
index medicus (1293) 1293
nootropic agents - pharmacology (1120) 1120
nootropic agents - therapeutic use (977) 977
neurosciences (916) 916
female (803) 803
pharmacology & pharmacy (768) 768
rats (762) 762
nootropic agents - administration & dosage (721) 721
memory (485) 485
alzheimer disease - drug therapy (484) 484
mice (477) 477
alzheimer's disease (471) 471
alzheimers-disease (464) 464
aged (441) 441
dose-response relationship, drug (411) 411
cognition - drug effects (405) 405
psychiatry (379) 379
disease models, animal (369) 369
brain (336) 336
memory - drug effects (335) 335
middle aged (333) 333
maze learning - drug effects (327) 327
rats, wistar (318) 318
clinical neurology (316) 316
treatment outcome (312) 312
nootropic agents - adverse effects (311) 311
cognition (302) 302
brain - drug effects (297) 297
adult (294) 294
dementia (289) 289
donepezil (253) 253
hippocampus - drug effects (250) 250
rats, sprague-dawley (245) 245
double-blind (240) 240
double-blind method (239) 239
time factors (236) 236
cognition disorders - drug therapy (235) 235
analysis (234) 234
neurology (208) 208
neuropsychological tests (207) 207
behavior, animal - drug effects (195) 195
hippocampus (193) 193
avoidance learning - drug effects (192) 192
piperidines - therapeutic use (190) 190
indans - therapeutic use (185) 185
brain - metabolism (184) 184
aged, 80 and over (183) 183
cholinesterase inhibitors - therapeutic use (178) 178
memory disorders - drug therapy (177) 177
neurons - drug effects (171) 171
behavioral sciences (165) 165
article (157) 157
hippocampus - metabolism (152) 152
oxidative stress (152) 152
motor activity - drug effects (146) 146
random allocation (146) 146
drug therapy (145) 145
geriatrics & gerontology (145) 145
long-term potentiation (141) 141
neuroprotective agents - pharmacology (141) 141
mice, inbred c57bl (140) 140
nootropic agents - pharmacokinetics (138) 138
cognitive ability (134) 134
neurons - metabolism (129) 129
research (128) 128
rat (127) 127
neurons (125) 125
placebo-controlled trial (124) 124
schizophrenia (120) 120
aging (118) 118
alzheimer disease - psychology (118) 118
acetylcholine (117) 117
administration, oral (117) 117
piperidines - administration & dosage (117) 117
piperidines - pharmacology (117) 117
chemistry, medicinal (115) 115
alzheimers disease (113) 113
indans - administration & dosage (112) 112
neuroprotective agents - therapeutic use (111) 111
efficacy (108) 108
young adult (105) 105
biomedicine (103) 103
health aspects (102) 102
spatial memory (102) 102
performance (101) 101
adolescent (100) 100
cholinesterase inhibitors - pharmacology (100) 100
cognition - physiology (100) 100
drug therapy, combination (100) 100
indans - pharmacology (100) 100
clinical trials (99) 99
cognition disorders - etiology (99) 99
drugs (99) 99
pharmacology (99) 99
drug administration schedule (98) 98
nootropic agents - chemistry (98) 98
rodents (98) 98
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2360) 2360
Russian (139) 139
German (27) 27
Japanese (17) 17
Spanish (13) 13
Hungarian (7) 7
Ukrainian (4) 4
Chinese (3) 3
French (3) 3
Italian (3) 3
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Clinical Nutrition, ISSN 0002-9165, 03/2015, Volume 101, Issue 3, pp. 538 - 548
Background: Recent evidence has indicated that flavanol consumption may have many health benefits in humans, including improved cognitive activities.... 
Lipid peroxidation | Insulin resistance | Cocoa flavanols | Blood pressure | Cognitive function | cognitive function | blood pressure | PROANTHOCYANIDINS | cocoa flavanols | PERFORMANCE | CHOCOLATE | FLAVAN-3-OLS | RICH COCOA | lipid peroxidation | IMPAIRMENT | CARDIOVASCULAR HEALTH | NUTRITION & DIETETICS | MOOD | INSULIN-RESISTANCE | insulin resistance | BRAIN | Beverages - adverse effects | Flavonols - adverse effects | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Flavonols - therapeutic use | Hypertension - drug therapy | Male | Cognition | Cognitive Dysfunction - prevention & control | Cacao - adverse effects | Aged, 80 and over | Aging | Female | Flavonols - administration & dosage | Hypertension - diet therapy | Double-Blind Method | Dairy Products - adverse effects | Cognitive Dysfunction - metabolism | Insulin Resistance | Nootropic Agents - therapeutic use | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Cacao - chemistry | Nootropic Agents - adverse effects | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Nootropic Agents - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Aged | Lipid Peroxidation | Cohort Studies | Medical research | Flavonoids | Flavones | Bioflavonoids | Nutritional aspects | Medicine, Experimental | Research | Cocoa | Health aspects
Journal Article
Journal of Nutritional Biochemistry, ISSN 0955-2863, 2015, Volume 26, Issue 7, pp. 736 - 744
Background: Neuroinflammation characterized by glial activation and release of proinflammatory mediators is considered to play a critical role in the... 
Oxidative stress | Neuroinflammation | Lycopene | Cognitive impairment | NEURODEGENERATIVE DISORDERS | LIPID-PEROXIDATION | NITRIC-OXIDE SYNTHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | MEMORY IMPAIRMENT | IMPROVES MEMORY | A beta(1-42) | NUTRITION & DIETETICS | AMYLOID-BETA | IN-VIVO | RAT-BRAIN | NF-KAPPA-B | Neuroprotective Agents - therapeutic use | Peptide Fragments | Rats, Wistar | Caspase 3 - chemistry | Caspase 3 - metabolism | Male | Cerebral Cortex - metabolism | Behavior, Animal | Carotenoids - adverse effects | Alzheimer Disease - prevention & control | Carotenoids - therapeutic use | Amyloid beta-Peptides | Neurons - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Alzheimer Disease - immunology | Neuroprotective Agents - administration & dosage | Disease Models, Animal | Exploratory Behavior | Memory Consolidation | Hippocampus - immunology | Cytokines - metabolism | Neurons - immunology | Nootropic Agents - therapeutic use | Random Allocation | Nootropic Agents - adverse effects | Hippocampus - metabolism | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Maze Learning | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Cerebral Cortex - immunology | Nootropic Agents - administration & dosage | Alzheimer Disease - metabolism | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Carotenoids - administration & dosage | Cytokines - antagonists & inhibitors
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 215 - 223
Phosphodiesterase 10A (PDE10A) is a novel target for the treatment of schizophrenia that may address multiple symptomatic domains associated with this... 
Schizophrenia | Phosphodiesterase 10A | Striatum | Cognition | OBJECT RETRIEVAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | IMMUNOHISTOCHEMICAL LOCALIZATION | STRIATUM-ENRICHED PHOSPHODIESTERASE | AMPA RECEPTOR | SYNAPTIC PLASTICITY | NEUROSCIENCES | PREFRONTAL CORTEX | MEMORY DYSFUNCTION | DOPAMINE-D-2 RECEPTOR OCCUPANCY | ANIMAL-MODELS | PHARMACOLOGY & PHARMACY | Pyrimidines - blood | Memory, Episodic | Male | Macaca mulatta | Cognition Disorders - prevention & control | Antipsychotic Agents - therapeutic use | Behavior, Animal - drug effects | Neurons - metabolism | Phosphorylation - drug effects | Pyridines - administration & dosage | Phosphodiesterase Inhibitors - pharmacokinetics | Rats | Random Allocation | Neurons - enzymology | Corpus Striatum - drug effects | Pyrimidines - pharmacokinetics | Phosphodiesterase Inhibitors - therapeutic use | Schizophrenia - metabolism | Rats, Wistar | Antipsychotic Agents - blood | Pyridines - pharmacokinetics | Molecular Targeted Therapy | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Protein Processing, Post-Translational - drug effects | Schizophrenia - physiopathology | Cognition Disorders - etiology | Neurons - drug effects | Corpus Striatum - enzymology | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Phosphoric Diester Hydrolases - metabolism | Schizophrenia - blood | Pyrimidines - administration & dosage | Nootropic Agents - pharmacokinetics | Nootropic Agents - therapeutic use | Antipsychotic Agents - pharmacokinetics | Nootropic Agents - blood | Phosphodiesterase Inhibitors - blood | Phosphoric Diester Hydrolases - chemistry | Antipsychotic Agents - administration & dosage | Nerve Tissue Proteins - metabolism | Phosphodiesterase Inhibitors - administration & dosage | Pyridines - blood | Animals | Nootropic Agents - administration & dosage | Pyrimidines - therapeutic use | Schizophrenia - drug therapy | Executive Function - drug effects | Enzymes | Plasma physics | Protein binding
Journal Article
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2015, Volume 14, Issue 4, pp. 388 - 405
Summary Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with... 
Neurology | CEREBRAL AMYLOID ANGIOPATHY | POSITRON-EMISSION-TOMOGRAPHY | TRAUMATIC BRAIN-INJURY | NITRIC-OXIDE SYNTHASE | ANTIINFLAMMATORY PREVENTION TRIAL | CENTRAL-NERVOUS-SYSTEM | RANDOMIZED CONTROLLED-TRIAL | MILD COGNITIVE IMPAIRMENT | TRANSGENIC MOUSE MODEL | CLINICAL NEUROLOGY | GENOME-WIDE ASSOCIATION | Humans | Astrocytes - pathology | Brain Injuries - complications | Brain Injuries - metabolism | Alzheimer Disease - pathology | Inflammation - metabolism | Microglia - immunology | Astrocytes - immunology | Alzheimer Disease - prevention & control | Inflammation Mediators - metabolism | Microglia - pathology | Inflammation - diagnosis | Alzheimer Disease - immunology | Disease Models, Animal | Inflammation Mediators - immunology | Severity of Illness Index | Immunization | Obesity - complications | Locus Coeruleus - pathology | Risk Factors | Clinical Trials as Topic | Inflammation - immunology | Biomarkers - blood | Immunity, Innate | Disease Progression | Protein Folding | Obesity - metabolism | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Nootropic Agents - administration & dosage | Alzheimer Disease - metabolism | Biomarkers - cerebrospinal fluid | Alzheimer Disease - genetics | Phagocytosis | Alzheimer's disease | Analysis | Genotype & phenotype | Neurosciences | Brain research | Pathogenesis | Cognitive ability | Ligands | Physiology | Mutation | Alzheimers disease | Gene expression | Immune system
Journal Article
AAPS Journal, ISSN 1550-7416, 04/2013, Volume 15, Issue 2, pp. 324 - 336
The therapeutic effects of curcumin in treating Alzheimer's disease (AD) depend on the ability to penetrate the blood-brain barrier. The latest nanoparticle... 
nanocurcumin | pharmacokinetic | Alzheimer's disease | oral route | behavior tests | PERMEABILITY | MEMORY DEFICITS | AMYLOID-BETA PROTEIN | FORMULATION | MICROPARTICLES | CELLULAR UPTAKE | BIOAVAILABILITY | MOUSE MODEL | A-BETA | CHEMOPREVENTIVE AGENT | PHARMACOLOGY & PHARMACY | Memory - drug effects | Curcumin - chemistry | Male | Polyethylene Glycols - chemistry | Curcumin - administration & dosage | Alzheimer Disease - pathology | Brain - metabolism | Nanoparticles | Plaque, Amyloid | Madin Darby Canine Kidney Cells | Behavior, Animal - drug effects | Female | Alzheimer Disease - psychology | Lactates - chemistry | Disease Models, Animal | Administration, Oral | Conditioning (Psychology) - drug effects | Drug Stability | Nootropic Agents - pharmacokinetics | Curcumin - pharmacokinetics | Alzheimer Disease - drug therapy | Mice, Transgenic | Technology, Pharmaceutical - methods | Nootropic Agents - blood | Permeability | Maze Learning - drug effects | Nootropic Agents - chemistry | Chemistry, Pharmaceutical | Blood-Brain Barrier - metabolism | Brain - drug effects | Particle Size | Fear | Povidone - chemistry | Animals | beta-Cyclodextrins - chemistry | Nootropic Agents - administration & dosage | Dogs | Brain - pathology | Mice | Alzheimer Disease - genetics | Nanotechnology | Alzheimer Disease - blood | Brain | Powders | Analysis | Drugstores | Medical tests | Cyclodextrins | Biopolymers | Polyols | Block copolymers
Journal Article
Journal Article
Journal Article